AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0853 IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2017
At a glance
- Drugs GDC 0853 (Primary)
- Indications B cell lymphoma; Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Genentech
- 17 Oct 2017 Planned End Date changed from 1 Jan 2017 to 29 Dec 2017.
- 17 Oct 2017 Planned primary completion date changed from 1 Jan 2017 to 29 Dec 2017.
- 01 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Jan 2017.